Á lódáil...
Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer
BACKGROUND. nab-Paclitaxel in combination with gemcitabine has emerged as a new treatment option for patients with metastatic pancreatic cancer (MPC), based on superiority over gemcitabine demonstrated in the phase III MPACT trial. Previously, Karnofsky performance status (KPS) score and the presenc...
Na minha lista:
Foilsithe in: | Oncologist |
---|---|
Main Authors: | , , , , , , , , , , , , |
Formáid: | Artigo |
Teanga: | Inglês |
Foilsithe: |
AlphaMed Press
2015
|
Ábhair: | |
Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4319641/ https://ncbi.nlm.nih.gov/pubmed/25582141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0394 |
Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|